To date, the U.S. FDA has approved two small-molecule inhibitors: tazemetostat (EPZ-6438) and valemetostat (DS-3201b), which target EZH2 or both EZH1 and EZH2 for cancer therapy. This evidence concerns the gene EZH2 and cancer.